

Electronic Certificate

Version: 1 . 0

Document Number: DK-AM2-2500036

Document Name: DK AM2 E-mail Kane video June 25 LU DRA

Country: Denmark

Product: AM2M

Type: Material

Sub Type: Mailing

Classification:

Material Intent: Promotional

Description: DK AM2 E-mail Kane video June 25 LU DRA

Target Audience: HCP

Method of Dissemination: E-Mailing

Certification Statement

We certify that the final electronic form of this material is in accordance with the regulations set forth by the health authority for the country of this document, and is a fair and truthful presentation of the facts about the product.

| Role | Signature |
|---|---|
| Arex Advisor - Compliance Approval (promotion@otsuka-europe.com) | Meaning: As the Compliance, I approve this document for use. Date: 01-Jul-2025 10:02:39 GMT+0000 |

{{customRichText:Required}}

Prelapase studiet er publiceret i JAMA Psychiatry i 2020 med bl.a. C. U. Correll, D. G. Robinson og John M. Kane som hovedforfattere.

John M. Kane fremhæver bl.a. at:

Studiet viser, det er muligt at få skizofrenipatienter tidligt i sygdomsforløbet til at acceptere behandling med LAI (Long Acting Injectable)¹

Brug af LAI (Long Acting Injectable) til skizofreni patienter tidligt i sygdomsforløbet kan signifikant reducere antallet af indlæggelser.¹

Du kan se interviewet i hyperlinket herunder:



{{customRichText:Required}}

Madeleine Rockler
madeleine.rockler@otsuka.se.invalid

Abilify Maintena® 960 mg er indiceret til vedligeholdelsesbehandling af skizofreni hos voksne patienter stabiliseret med aripiprazol.²

Ref.

1.Kane JM, *et al.* JAMA Psychiatry 2020; e202076

2.Abilify Maintena produktresumé

[Læs pligteksten her om Abilify Maintena® \(aripiprazol\)](#)



Otsuka Pharma Scandinavia AB
Sveavägen 151
113 46 Stockholm, Sweden
+46 545 286 60, www.otsuka.dk

Your personal data will be processed in accordance with the Otsuka HCP Privacy Notice, which is available [here](#). If you would like to withdraw your consent, you can unsubscribe to receiving emails related to this Therapy Area at any time and without reason by clicking on the unsubscribe link below or by emailing privacy@otsuka-europe.com.

[Unsubscribe](#)

Please send adverse events and/or product quality complaints to: opsab.vigilance@otsuka.se and medical information enquiries in English to: medical.information@otsuka-europe.com

DK-AM2-2500036 v 1.0. Date of preparation: 2025-06-25
